ACE inhibitors or ARBs are preferred in both diabetic and non-diabetic CKD patients with either microalbuminuria (range, 30 to 300 mg/day) or macroalbuminuria (>300 mg/day). This evidence concerns the gene ACE and chronic kidney disease.